Medizone Home
×

Medizone and PassionBio agree on closer cooperation

PassionBio’s provides drug development, regulatory and commercial solutions for biologics, biosimilar/-better or mAb programs. Our aim is to foster cross-frontier development of your biosimilar portfolio. We ...

New EU GDP Guidelines – Part II

The “Guidelines on Good Distribution Practice of Medicinal Products for Human Use” have been published 07.03.2013. But only a few months later the GDP had to be renewed. The new version 2013/C 343/01 ...

Apotex Canada received its first Biosimilar registration in Europe of Amgen’s blockbuster cancer treatment filgrastim!

Apotex's version of filgrastim received regulatory approval from the European Commission. Out-of-patent filgrastim, a biologic drug branded as Neupogen by Amgen and as Grastofil by Apotex, is used to boost ...

Celltrion files for approval of trastuzumab (Herceptin) biosimilar (CT-P6) in Korea

On June 4th Celltrion officially announced that it has filed for Ministry of Food and Drug Safety (MFDS, formerly the Korea Food and Drug Administration) approval of CT-P6 with same indications of the original ...
Pages:12»